

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Zydelig (idelalisib)

Override(s)	Approval Duration
Prior Authorization	Initial: 6 months
Quantity Limit	Maintenance: 6 months

Medications	Quantity Limit
Zydelig (idelalisib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Zydelig (idelalisib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Relapsed/refractory/progressive chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL); **OR**
 - B. Relapsed/refractory/progressive Follicular lymphoma; **OR**
 - C. Relapsed/refractory/progressive Primary Cutaneous B-cell lymphoma (NCCN 2A); **OR**
 - D. Relapsed/refractory/progressive MALT Lymphoma (NCCN 2A); **OR**
 - E. Relapsed/refractory/progressive Nodal or Splenic Marginal Zone Lymphoma (NCCN 2A).

Requests for continuation of therapy for follicular lymphoma with Zydelig (idelalisib) may be approved if the following criteria are met:

- I. Individual has achieved and sustained continuing clinical benefit (e.g. complete response, partial response, or stable disease); **AND**
- II. Documentation has been provided.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Note: Zydelig (idelalisib) labeling includes black box warnings for hepatotoxicity, severe diarrhea, colitis, pneumonitis and intestinal perforation. Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients, and fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 10/2017.

DrugPoints® System [Internet Database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2017 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.